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Abstract There are a large number of drugs inducing
headache as an adverse reaction. Nevertheless, headaches
as adverse reactions to drugs have received limited atten-
tion. Non-serious adverse reactions, such as headache, are
not quantified and described as accurately as serious, life
threatening ones. However, non-serious reactions can also
be extremely troublesome, above all when they are
chronic: they can affect patients’ quality of life and con-
tribute to non-compliance. It is absolutely possible that the
number of patients with headache as an adverse reaction,
which is going to increase, considering the growing use of
medications. Physicians should, therefore, be aware of this
issue. Indeed, it is difficult to attribute the diagnosis of
adverse drug reaction to a condition, headache, which is
also a very common symptom in general population.
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Introduction
Headaches as adverse reactions to drugs have not been
much studied both in the field of pharmacovigilance, and
by headache clinicians and researchers, even if a very large
number of drugs, with different mechanisms of action, can
induce headache in acute or chronic treatment or after drug
discontinuation [1]. The aims of this paper are (1)
underscoring the lack of information on headache as an
adverse reaction, and (2) stimulate to recognize the kind of
adverse reaction headache, in order to properly treat it.
Adverse reactions
Medications are classified according to their main thera-
peutic action, but no drug induces only one specific effect.
Drugs can be selective, but they are rarely specific. They
induce two kinds of effects: those useful for treatment and
those non-relevant to this aim and unintended. The latter
are defined ‘‘side effects’’ or, more specifically, adverse
reactions. An adverse drug reaction (ADR) is a response to
a drug that is noxious and unintended and occurs at doses
normally used in people for the prophylaxis, diagnosis or
therapy for the disease, or for modification of physiological
function [2]. Adverse reactions are classified into serious
and non-serious or low-risk reactions. A serious reaction is
one that results in death, requires hospital admission or
prolongation of existing hospital stay, results in persistent
or significant disability/incapacity, or is life threatening [3].
Adverse reactions are categorized into five types, the
most important of which are type-A (augmented), dose-
dependent, and type-B (bizarre), non-dose-dependent [4].
Most adverse reactions, approximately 75% [5], belong to
type-A [6]. These ADRs are relatively easy to diagnose,
since they can be predicted according to the main action of
the drug and are, therefore, generally identified in the study
preceding the marketing of the drug. They have high
morbidity, but are practically never life threatening. Fur-
thermore, they can disappear if drug dosage is reduced [6].
Type-B reactions are also termed idiosyncratic, owing to
their unpredictable nature and our lack of understanding of
the mechanisms involved. There is no dose–response
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relationship, incidence is very low (\1/1,000), but they are
often serious and potentially life threatening. They are
often not detected until the drug has been released onto the
market and they are sometimes detected even after years of
use. Type-B reactions, therefore, represent a major clinical
problem [7]. Type-C reactions (arising from chronic use)
are induced by the long-term effect of the drug and its
metabolites: for example, the long-term toxicity of amio-
darone. Type-D (delayed) is adverse reactions that appear
later and are more serious than type-C: for example,
bladder cancer in patients who had been treated for a long
period with cyclophosphamide. Type-E reactions (end of
treatment) arise from discontinuing treatment [8].
The identification of ADRs has remarkably improved in
the last decades [9]. Nevertheless, reactions that are not life
threatening are not systematically studied and quantified
with the same accuracy as those which are considered
serious [10]. Serious events are five times more likely to be
reported than non-serious ones [11, 12]. Even when they
are reported, non-serious ADRs are often not described in
detail, unless the event is a study endpoint or it is of par-
ticular interest. This is unfortunate, because non-serious
ADRs can be very worrying [13], above all when they are
chronic: they can affect patients’ quality of life, reduce
adherence to treatment or cause drug discontinuation
[10, 14, 15].
There are various information sources about ADRs. The
most important ones are randomized controlled trials,
epidemiological post-marketing studies, and spontaneous
reporting [16]. ADR headache is very frequent, whatever
the source is. However, information about this ADR is
usually limited and does not allow a precise assessment.
Clinical trials should, therefore, be able to determine ADR
headache more accurately; above all, when the drug stud-
ied is related to a previously marketed compound able to
induce headache, or its mechanism of action can suppos-
edly cause headache. Moreover, when the results of clinical
trials are published, the proportion of patients that dis-
continued drug treatment as a consequence of headache
should also be reported together with a detailed description
of the characteristics of the symptom and of the patients.
The actual frequency of an ADR headache is only
known when a drug has been studied both in patients taking
it and in placebo group. The importance of this datum is
also stressed in ICHD-II [17], which specifies in chapter
8.1 that ‘‘only when headache occurs more often after
active drug than after placebo in double blind trials it can
be regarded as true effect’’. Nevertheless, the placebo
effect can substantially vary across trials with the same
drug [18]. The frequency of ADR headache can also be
influenced by the presence of headache sufferers, who
could be much more susceptible to this adverse reaction
than non-headache subjects [17]. Patients should therefore
be screened to detect headache before clinical trial enrol-
ment and headache sufferers should be separately assessed.
ADR headache
ICDH-II [17] includes secondary headaches attributed to
drugs or their withdrawal, which can be fully considered
adverse reactions to drugs, in chapter 8, codes 8.1, 8.3, and
8.4. Many other ADR headaches have also been less
studied and characterized that in lacking elements for a
more accurate description, ICHD-II itself [17] only gives a
list of the drugs, which can induce them in the appendix.
The two mechanisms inducing headache as an adverse
reaction have been classically considered: one is vasodi-
latation and the other is raised intracranial pressure.
Vasodilatation explains headache induced by most car-
diovascular drugs such as calcium-channel blockers and
ACE inhibitors. In these cases, headache is a side effect
related to the primary pharmacological action of the drug,
it is often dose-dependent, but it already appears with the
dosages normally used in therapy. Headache related to
aseptic meningitis induced by drugs is instead a type-B
adverse reaction, not predictable from the mechanism of
action of the medication that induces it [1].
Many ADR headaches can have the characteristics of
migraine, tension-type headache or cluster headache
(Table 1) and could therefore contribute to the high indi-
vidual and social cost of these diseases. The burden asso-
ciated with primary headache is a major public health
problem [19]. In a retrospective study carried out in the
Netherlands [20], headache was the third ADR most fre-
quently reported by patients and even the first reported by
Table 1 Characteristics of headaches attributed to drugs and drug classes
Characteristic Drug
Migraine without aura Cyclosporin [31], Dipyridamole [32], Nitric oxide donors [33], Phosphodiesterase inhibitors [34],
Interferon-b [35], Ondansetron [36], Tacrolimus [37], Sertraline [38]
Migraine with aura Nitric oxide donors [39], Phosphodiesterase inhibitors [34], Tacrolimus [40], Fluoxetine [41]
Typical aura without headache Tadalafil [42]
Cluster headache Nitric oxide donors [43], Phosphodiesterase inhibitors [44]
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health-care professionals in the year 2004–2007. Patients
only report reactions which they consider important; they
do not instead report the ones which they consider non-
serious, unless they are specifically questioned (which has
not been done in this study). These results therefore indi-
cate that, even if it was considered non-serious, headache
was very important, both for patients and for health-care
professionals. There are no standardized and universal
rating scales to categorize the severity of ADR. There is no
single risk–benefit evaluation for a drug; it is context-
dependent [21]. For example, the risk of headache induced
by an immunosuppressant treatment is less important than
the benefit, whereas it becomes more relevant in cases that
only require anti-acid therapy.
Considering the growing number of people taking drugs
[22], headache clinicians are likely to treat patients with
polymedication and headaches as ADRs, difficult to diag-
nose and manage. In this context, every time a patient
reports the onset of a headache he had never suffered from
or the worsening of or change in the headache he has been
suffering from for a long time, the physician shall also take
into consideration, in differential diagnosis, that this
headache can be an adverse reaction to a drug. An accurate
pharmacological anamnesis is fundamental in order to
diagnose headache as an adverse reaction. Nevertheless, it
can be very difficult to attribute the diagnosis of ADR to a
condition such as headache, which is also a common
symptom, not pathognomonic of any pathological condi-
tion, and extremely widespread among general population
(the percentage of the adult population with an active
headache disorder is 47% for headache in general) [23].
Primary headaches, such as ADRs, are prevalent in females
[24]. In clinical practice, the consequences of this fact are
probably reduced because episodic primary headaches
mainly affect young adults who take few medications [23].
However, a large number of chronic headache patients
attend a tertiary clinic and the majority of them are elderly
women with multiple co-morbid conditions and polyphar-
macy [24, 25], and therefore are at a higher risk of ADRs
[26].
In order to define the causal relationship between drug
and adverse reaction, the time elapsed between the onset of
headache and the administration of the drug must be con-
sidered and it must be assessed if the headache is com-
patible with the well-known pharmacological properties of
the substance. However, the best proofs of the causal
relationship are the disappearing of headache after dis-
continuing the drug and its onset when the patient takes the
medication again [27].
Failing to detect ADR headache can cause patients’
suffering, anxiety, worrying, and a high social cost: diag-
nostic tests, other physicians’ consultations, and prescrip-
tion of more drugs, while the solution is exactly the
opposite, i.e., to reduce the number of drugs [28].
Researchers should also be interested in ADR headache,
considering the fundamental role that drugs have had and
will have in deepening the knowledge of pathogenetic
mechanisms of primary headaches. An example is NO
donors. These drugs have been widely used in experimental
models and diagnostic tests to study headaches [29].
Table 2 Classification of ADR headaches according to the type of adverse reaction (drug-induced headaches reported in ICHD-II have not been
included when there are no elements proving or suggesting the causal link between drug and headache)
Headache type Drugs implied
1. Headache as type-A adverse drug reaction:
predictable, related to the principal
pharmacological action of the drugs, and dose-
dependent
Nitric oxide (NO) donors (code 8.1.1), Phosphodiesterase (PDE) inhibitors (code 8.1.2),
Calcitonin gene-related peptide-CGRP (code 8.1.9), Cocaine (code 8.1.6), Ethanol
(code 8.1.4), Cannabis (code 8.1.7), Histamine (code 8.1.8), Calcium-channel
blockers (Table 1 in the appendix), Antiarrhytmics, b-Adrenergic blockers, Ace
inhibitors, Sympathomimetics (code 10.3.6), Antagonists of the at-1 receptors for
Angiotensin II, Statins, a2-Adrenergic agonist (Clonidine), a1-Adrenergic blockers
(Doxazosin and Prazosin), Amiloride, Methylxanthines, b2-Adrenergic agonists,
Agents for erectile dysfunction, Ergotamine (Table 1 in the appendix), Nicotine
(code 8.1.10), Amphetamine (code 10.3.6)
2. Headache as type-B adverse drug reaction:
idiosyncratic, unpredictable, and related to
aseptic meningitis (code 7.3.2)
Amoxicillin, Carbamazepine, Diclofenac, Famotidine, Ibuprofen, Immune globulin,
Infliximab, Ketorolac, Leflunomide, Levamisole, Metronidazole, Naproxen,
Ranitidine, Rofecoxib, Sulfamethoxazole, Sulfasalazine, Sulindac, Tolmetin,
Trimethoprim, Valacyclovir
3. Headache as type-C adverse drug reaction:
after chronic medication, related to raised
intracranial pressure (code 8.3 and code 7.1.2)
Amiodarone, Anabolic steroids, Contraceptives Combination, Ciprofloxacin, Danazol,
Corticosteroids, Gentamicin, Lithium Carbonate, Nalidixic Acid, Nitrofurantoin,
Ofloxacin, Retinoic Acid, Tetracycline, Thyroid hormone replacement, Vitamin A
4. Headache as type-E adverse drug reaction:
related to substance withdrawal
Caffeine-withdrawal headache (code 8.4.1), Opioid-withdrawal headache (code 8.4.2),
estrogen-withdrawal headache (code 8.4.3), Ergotamine-withdrawal headache,
Cocaine-withdrawal headache, Methysergide-withdrawal headache
* The codes reported in ICHD-II are in brackets
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In order to give more elements to recognize and treat
adverse reaction headaches, drug-induced headaches
[excluding medication-overuse headache (code 8.2)]
included in chapter 8 of the International Classification of
Headache Disorders (ICHD-II) could also be classified
according to the criteria and terminology used to categorize
adverse reactions in the field of pharmacovigilance
(Table 2). This classification stresses the pathophysiologi-
cal basis of these ‘‘headaches induced by drug use’’, an
essential element to classify them as secondary. Further-
more, it suggests immediately the possible management of
type-A adverse reaction headaches, that is to say, the
reduction of drug dosage. This classification has some
limitations, due to the uncertainty inherent in the different
sources. However, we excluded drugs inducing percentages
of headache lower than those induced by placebo. It should
also be stressed in Table 2 that ADR headaches which
clearly show the causal link between drug and headache are
those classified into A and E types. The hypothesis of
causal relationship is often only formulated considering the
evolution of case reports in type-C headaches.
Classifications are very important to organize and
manage knowledge and establish relationships between
the various pieces of information. The classification of
the International Headache Society has become a diffused
standard in World wide communications between research-
ers and clinicians. The methods used to analyze and assess
drug safety are more and more precise [30]. In this context,
we also propose that clinical trials also assess if the side
effect headache has or has not characteristics resembling
migraine, tension-type headache or cluster headache. This
effort should allow accurate descriptions of the headache’s
characteristics before drug approval and it should make
the diagnosis of ADR headache easier in clinical practice
after the drug is marketed.
We hope that the sharing of the classification used in the
field of pharmaco-vigilance and headaches will improve
the management of patients’ problems.
Conflict of interest None.
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